DK0804196T3 - Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia - Google Patents
Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgiaInfo
- Publication number
- DK0804196T3 DK0804196T3 DK95916611T DK95916611T DK0804196T3 DK 0804196 T3 DK0804196 T3 DK 0804196T3 DK 95916611 T DK95916611 T DK 95916611T DK 95916611 T DK95916611 T DK 95916611T DK 0804196 T3 DK0804196 T3 DK 0804196T3
- Authority
- DK
- Denmark
- Prior art keywords
- fibromyalgia
- treatment
- serotonin antagonists
- antagonists
- serotonin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9406857A GB9406857D0 (en) | 1994-04-07 | 1994-04-07 | Improvements in or relating to organic compounds |
PCT/EP1995/001264 WO1995027490A1 (en) | 1994-04-07 | 1995-04-06 | Use of serotonin antagonists (5ht3) for treating fibromyalgia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0804196T3 true DK0804196T3 (da) | 2003-01-27 |
Family
ID=10753131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95916611T DK0804196T3 (da) | 1994-04-07 | 1995-04-06 | Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia |
Country Status (22)
Country | Link |
---|---|
US (2) | US5773436A (da) |
EP (1) | EP0804196B1 (da) |
JP (1) | JP2818303B2 (da) |
KR (1) | KR100415181B1 (da) |
CN (1) | CN1084618C (da) |
AT (1) | ATE225176T1 (da) |
AU (1) | AU706279B2 (da) |
CA (1) | CA2186844C (da) |
CZ (1) | CZ290359B6 (da) |
DE (1) | DE69528475T2 (da) |
DK (1) | DK0804196T3 (da) |
ES (1) | ES2184797T3 (da) |
FI (1) | FI118034B (da) |
GB (1) | GB9406857D0 (da) |
HU (1) | HU226892B1 (da) |
MX (1) | MX9604589A (da) |
NO (1) | NO312745B1 (da) |
PL (1) | PL316658A1 (da) |
PT (1) | PT804196E (da) |
RU (1) | RU2165760C2 (da) |
SK (1) | SK281603B6 (da) |
WO (1) | WO1995027490A1 (da) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997045425A1 (en) * | 1996-05-27 | 1997-12-04 | Fujisawa Pharmaceutical Co., Ltd. | New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
US6696495B2 (en) * | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
JP2002537255A (ja) | 1999-02-18 | 2002-11-05 | ノバルティス アクチエンゲゼルシャフト | リウマチ性炎症性プロセスに対する5−ht3レセプターアンタゴニストの全身的使用 |
JP2002537245A (ja) * | 1999-02-18 | 2002-11-05 | ノバルティス アクチエンゲゼルシャフト | 5−ht3レセプターアンタゴニストの使用 |
TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
GB9918425D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
BR0213612A (pt) | 2001-10-02 | 2004-08-24 | Upjohn Co | Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição |
AU2002339810A1 (en) * | 2001-10-16 | 2003-04-28 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
US6894042B2 (en) | 2002-02-19 | 2005-05-17 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
WO2003070732A1 (en) | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
WO2003100091A1 (en) * | 2002-05-24 | 2003-12-04 | Epidauros Biotechnologie Ag | Means and methods for improved treatment using 'setrones' |
SK288115B6 (sk) | 2002-09-25 | 2013-09-03 | Memory Pharmaceuticals Corporation | Indazoles, pharmaceutical compositions comprising them and their use |
NZ541008A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating functional bowel disorders |
DE602004005814T2 (de) * | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
RU2389729C2 (ru) * | 2003-12-22 | 2010-05-20 | Мемори Фармасьютиклз Корпорейшн | 1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение |
TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
JP4995075B2 (ja) * | 2004-03-25 | 2012-08-08 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用 |
US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
DE602005024677D1 (de) * | 2004-04-22 | 2010-12-23 | Memory Pharm Corp | Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen |
ATE505470T1 (de) * | 2004-05-07 | 2011-04-15 | Memory Pharm Corp | 1h-indazole, benzothiazole, 1,2-benzisoxazole, 1, 2-benzisothiazole und chromone und deren herstellung und verwendungen |
JP5042028B2 (ja) * | 2004-11-05 | 2012-10-03 | セラヴァンス, インコーポレーテッド | キノリノン−カルボキサミド化合物 |
JP5086091B2 (ja) * | 2004-11-05 | 2012-11-28 | セラヴァンス, インコーポレーテッド | 5−ht4受容体アゴニスト化合物 |
CN101080406A (zh) * | 2004-12-22 | 2007-11-28 | 施万制药 | 吲唑-甲酰胺化合物 |
DE602005019094D1 (de) * | 2004-12-22 | 2010-03-11 | Memory Pharmaceutical Corp | Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns |
JP5042043B2 (ja) * | 2005-03-02 | 2012-10-03 | セラヴァンス, インコーポレーテッド | 5−ht4レセプターアゴニストであるキノリン化合物 |
WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
ES2743153T3 (es) | 2009-11-06 | 2020-02-18 | Sk Biopharmaceuticals Co Ltd | Métodos para tratar el síndrome de fibromialgia |
JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
US10329306B2 (en) | 2014-09-29 | 2019-06-25 | Takeda Pharmaceutical Company Limited | Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3650772T2 (de) * | 1985-04-27 | 2003-04-03 | F. Hoffmann-La Roche Ag, Basel | Derivate von Indazole-3-carboxamide und -3-carboxylsäure |
GB8623142D0 (en) * | 1986-09-26 | 1986-10-29 | Beecham Group Plc | Compounds |
-
1994
- 1994-04-07 GB GB9406857A patent/GB9406857D0/en active Pending
-
1995
- 1995-04-06 HU HU9602721A patent/HU226892B1/hu not_active IP Right Cessation
- 1995-04-06 AT AT95916611T patent/ATE225176T1/de not_active IP Right Cessation
- 1995-04-06 JP JP7526064A patent/JP2818303B2/ja not_active Expired - Fee Related
- 1995-04-06 CA CA002186844A patent/CA2186844C/en not_active Expired - Fee Related
- 1995-04-06 PL PL95316658A patent/PL316658A1/xx unknown
- 1995-04-06 SK SK1278-96A patent/SK281603B6/sk not_active IP Right Cessation
- 1995-04-06 WO PCT/EP1995/001264 patent/WO1995027490A1/en active IP Right Grant
- 1995-04-06 MX MX9604589A patent/MX9604589A/es not_active IP Right Cessation
- 1995-04-06 CZ CZ19962915A patent/CZ290359B6/cs not_active IP Right Cessation
- 1995-04-06 ES ES95916611T patent/ES2184797T3/es not_active Expired - Lifetime
- 1995-04-06 KR KR1019960705579A patent/KR100415181B1/ko not_active IP Right Cessation
- 1995-04-06 RU RU96121561/14A patent/RU2165760C2/ru not_active IP Right Cessation
- 1995-04-06 US US08/721,988 patent/US5773436A/en not_active Expired - Lifetime
- 1995-04-06 PT PT95916611T patent/PT804196E/pt unknown
- 1995-04-06 DK DK95916611T patent/DK0804196T3/da active
- 1995-04-06 AU AU23052/95A patent/AU706279B2/en not_active Ceased
- 1995-04-06 EP EP95916611A patent/EP0804196B1/en not_active Expired - Lifetime
- 1995-04-06 CN CN95192946A patent/CN1084618C/zh not_active Expired - Fee Related
- 1995-04-06 DE DE69528475T patent/DE69528475T2/de not_active Expired - Lifetime
-
1996
- 1996-10-04 NO NO19964236A patent/NO312745B1/no not_active IP Right Cessation
- 1996-10-04 FI FI964004A patent/FI118034B/fi not_active IP Right Cessation
-
1998
- 1998-05-18 US US09/080,605 patent/US5985866A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0804196T3 (da) | Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia | |
TR199801255T2 (xx) | Vitronektin resept�r antagonistleri. | |
NO960630D0 (no) | Heterocykler anvendelige som neurokinin antagonister | |
EA199800667A1 (ru) | Новые фенантридины | |
DK0674641T3 (da) | Pyrrolopyrimidiner som CRF-antagonister | |
MY131298A (en) | 5-heteroyl indole derivatives | |
TR200000374T2 (tr) | Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi. | |
DK0710444T3 (da) | Apparat til behandling af fjerkræ ophængt i benene | |
EA199700061A1 (ru) | Способ получения силденафила | |
DK0386997T3 (da) | Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler | |
TR199801348T2 (xx) | Heterosikl-kondanse morfinoid t�revleri(II). | |
ES2184077T3 (es) | Nuevas fenantridinas sustituidas en la posicion 6. | |
DE59100670D1 (de) | Bausatz zur herstellung von büro-arbeitstischen. | |
DE69524623D1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
ATE347372T1 (de) | Vakzine zur behandlung von mycosen | |
ATE198202T1 (de) | Fibrinogen receptor antagonisten | |
IS4367A (is) | CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín | |
DE69110456D1 (de) | Vorrichtung zum zwischenschichtplanieren von halbleitern. | |
EA199900534A1 (ru) | Имидазопиридазины | |
DE3669063D1 (de) | Verfahren zur desinfektion von lokalen gegen kokkizide oozysten. | |
NO20005548D0 (no) | Mykobakterieinhibitorer | |
EA200500878A1 (ru) | Кальцилитические соединения | |
DK192890D0 (da) | 24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme | |
BR0113266A (pt) | Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla | |
TR199701011A2 (xx) | 1-karba-(detia)-sefalosforin t�revleri. |